Melatonin MT1 and MT2 receptors display different molecular pharmacologies only in the G-protein coupled state

British Journal of Pharmacology

Volumn 171, Issue 1, 2014, Pages 186-201

  Legros, Céline ^a   Devavry, Séverine ^a,b,c   Caignard, Sarah ^a   Tessier, Clémence ^a,d   Delagrange, Philippe ^a   Ouvry, Christine ^a   Boutin, Jean A ^a   Nosjean, Olivier ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b UMR85 PHYSIOLOGIE DE LA REPRODUCTION ET DES COMPORTEMENTS   (France)

^c CNRS   (France)

^d Novartis Pharmaceuticals UK Limited   (United Kingdom)

Author keywords

3H melatonin; coupling state; GTP S; melatonin; melatonin receptors

Indexed keywords

2 AMINOTETRALIN DERIVATIVE; 2 IODOMELATONIN; 4 PHENYL 2 PROPIONAMIDOTETRALINE; 6 CHLOROMELATONIN; GALLOPAMIL; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); LUZINDOLE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN DERIVATIVE; RAMELTEON; SODIUM CHLORIDE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL LINE; CELL MEMBRANE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DISSOCIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BINDING; SPECIES DIFFERENCE; WHOLE CELL;

COUPLING STATE; GTPΓS; MELATONIN; MELATONIN RECEPTORS; [3H]-MELATONIN;

ANIMALS; BINDING SITES; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; GTP-BINDING PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HEK293 CELLS; HUMANS; KINETICS; LIGANDS; MELATONIN; MICE; MOLECULAR SEQUENCE DATA; RADIOLIGAND ASSAY; RATS; RECEPTOR, MELATONIN, MT2; SHEEP; SODIUM CHLORIDE; SPECIES SPECIFICITY; TRANSFECTION;

EID: 84890294469     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12457     Document Type: Article

References (41)

1. Acuna-Castroviejo D, Reiter RJ, Menendez-Pelaez A, Pablos MI, Burgos A, (1994). Characterization of high-affinity melatonin binding sites in purified cell nuclei of rat liver. J Pineal Res 16: 100-112.
2. Alexander SPH, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Overview. Br J Pharmacol 170: 1449-1867.
3. Audinot V, Mailliet F, Lahaye-Brasseur C, Bonnaud A, Le Gall A, Amosse C, et al. (2003). New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol 367: 553-561.
4. Audinot V, Bonnaud A, Grandcolas L, Rodriguez M, Nagel N, Galizzi JP, et al. (2008). Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors. Biochem Pharmacol 75: 2007-2019.
5. Ayoub MA, Couturier C, Lucas-Meunier E, Angers S, Fossier P, Bouvier M, et al. (2002). Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J Biol Chem 277: 21522-21528.
6. Ayoub MA, Levoye A, Delagrange P, Jockers R, (2004). Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared to MT2 homodimers. Mol Pharmacol 66: 312-321.
7. Birnbaumer L, Abramowitz J, Brown AM, (1990). Receptor-effector coupling by G proteins. Biochim Biophys Acta 1031: 163-224.
8. Bradford MM, (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
9. Browning C, Beresford I, Fraser N, Giles H, (2000). Pharmacological characterization of human recombinant melatonin mt(1) and MT(2) receptors. Br J Pharmacol 129: 877-886.
10. 50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
11. Cogé F, Guenin SP, Fery I, Migaud M, Devavry S, Slugocki C, et al. (2009). The end of a myth: cloning and characterization of the ovine melatonin MT(2) receptor. Br J Pharmacol 158: 1248-1262.
12. Depreux P, Lesieur D, Mansour HA, Morgan P, Howell HE, Renard P, et al. (1994). Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands. J Med Chem 37: 3231-3239.
13. Devavry S, Legros C, Brasseur C, Cohen W, Guenin SP, Delagrange P, et al. (2012a). Molecular pharmacology of the mouse melatonin receptors MT(1) and MT(2). Eur J Pharmacol 677: 15-21.
14. Devavry S, Legros C, Brasseur C, Delagrange P, Spadoni G, Cohen W, et al. (2012b). Description of the constitutive activity of cloned human melatonin receptors hMT(1) and hMT(2) and discovery of inverse agonists. J Pineal Res 53: 29-37.
15. Drew JE, Barrett P, Mercer JG, Moar KM, Canet E, Delagrange P, et al. (2001). Localization of the melatonin-related receptor in the rodent brain and peripheral tissues. J Neuroendocrinol 13: 453-458.
16. Dubocovich ML, (1995). Melatonin receptors: are there multiple subtypes? Trends Pharmacol Sci 16: 50-56.
17. Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J, (2010). International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 62: 343-380.
18. Ersahin C, Masana MI, Dubocovich ML, (2002). Constitutively active melatonin MT(1) receptors in male rat caudal arteries. Eur J Pharmacol 439: 171-172.
19. 2C antagonist. ChemMedChem. in press
20. Jockers R, Maurice P, Boutin JA, Delagrange P, (2008). Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new? Br J Pharmacol 154: 1182-1195.
21. Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, et al. (2010). Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 71: 109-120.
22. Kennaway DJ, Hugel HM, (1992). Melatonin binding sites: are they receptors? Mol Cell Endocrinol 88: C1-C9.
23. Kennaway DJ, Hugel HM, Rowe SA, (1994). Characterization of the chicken brain melatonin-binding protein using iodinated and tritiated ligands. J Pineal Res 17: 137-148.
24. 2 melatonin receptors. Int J Mol Sci 14: 8948-8962.
25. Mailliet F, Audinot V, Malpaux B, Bonnaud A, Delagrange P, Migaud M, et al. (2004). Molecular pharmacology of the ovine melatonin receptor: comparison with recombinant human MT1 and MT2 receptors. Biochem Pharmacol 67: 667-677.
26. Masana MI, Dubocovich ML, (2001). Melatonin receptor signaling: finding the path through the dark. Sci STKE 2001: PE39.
27. Mazzucchelli C, Pannacci M, Nonno R, Lucini V, Fraschini F, Stankov BM, (1996). The melatonin receptor in the human brain: cloning experiments and distribution studies. Brain Res Mol Brain Res 39: 117-126.
28. Morgan PJ, Barrett P, Howell HE, Helliwell R, (1994). Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem Int 24: 101-146.
29. Niles LP, (1987). [3H] melatonin binding in membrane and cytosol fractions from rat and calf brain. J Pineal Res 4: 89-98.
30. Nonno R, Lucini V, Pannacci M, Mazzucchelli C, Angeloni D, Fraschini F, et al. (1998). Pharmacological characterization of the human melatonin Mel1a receptor following stable transfection into NIH3T3 cells. Br J Pharmacol 124: 485-492.
31. Nonno R, Fraschini F, Stankov BM, (1999). Methods for the evaluation of drug action at the human melatonin receptor subtypes. Biol Signals Recept 8: 32-40.
32. Piketty V, Pelletier J, (1993). Melatonin receptors in the lamb pars tuberalis/median eminence throughout the day. Neuroendocrinology 58: 359-365.
33. Reppert SM, Weaver DR, Ebisawa T, (1994). Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 13: 1177-1185.
34. Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA, Gusella JF, (1995). Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci U S A 92: 8734-8738.
35. Vakkuri O, Lamsa E, Rahkamaa E, Ruotsalainen H, Leppaluoto J, (1984). Iodinated melatonin: preparation and characterization of the molecular structure by mass and 1H NMR spectroscopy. Anal Biochem 142: 284-289.
36. Williams LM, Hannah LT, Hastings MH, Maywood ES, (1995). Melatonin receptors in the rat brain and pituitary. J Pineal Res 19: 173-177.
37. Williams LM, Hannah LT, Bassett JM, (1999). Melatonin receptors in neonatal pig brain and pituitary gland. J Pineal Res 26: 43-49.
38. Witt-Enderby PA, Dubocovich ML, (1996). Characterization and regulation of the human ML1A melatonin receptor stably expressed in Chinese hamster ovary cells. Mol Pharmacol 50: 166-174.
39. Ying SW, Niles LP, (1991). 3-[(3-cholamidopropyl)dimethylammonio]-1- propane sulfonate-solubilized binding sites for 2-[125I]iodomelatonin in chick brain retain sensitivity to guanine nucleotides. J Neurochem 56: 580-586.
40. Zawilska JB, Skene DJ, Arendt J, (2009). Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol Rep 61: 383-410.
41. Zlotos DP, Attia MI, Julius J, Sethi S, Witt-Enderby PA, (2009). 2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists. J Med Chem 52: 826-833.